{ "items": [ "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n MEASUREMENT OF MICRORNA EXPRESSION LEVELS BY QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION IS A USEFUL TOOL TO PREDICT OUTCOME IN PATIENTS WITH B CELL CHRONIC LYMPHOCYTIC LEUKAEMIA\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Binding of monoclonal anti-interleukin 2 antibody to nucleoli in acute leukemia blast cells.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n The role of the physician in laboratory medicine: a European perspective.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Establish good genomic practice to guide medicine forward.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n NOVEL GENE DELETIONS RESULT IN HAEMOCHROMATOSIS\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n A NOVEL TMPRSS6 MUTATION IN 2 BULGARIAN SIBLINGS\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n ESTIMATING DISEASE PENETRANCE IN P.C282Y HOMOZYGOTES IN THE UK\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n COMPREHENSIVE GENETIC TESTING IS REQUIRED FOR PATIENTS WITH UNEXPLAINED IRON OVERLOAD\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN FOR MUTATIONS IN 16 GENES INVOLVED IN IRON HOMEOSTASIS AS AN AID TO GENETIC DIAGNOSIS FOR PATIENTS WITH IRON OVERLOAD OR IRON DEFICIENCY\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n JUVENILE HAEMOCHROMATOSIS MUTATIONS ARE NOT THAT SIMPLE\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Recombinant urate oxidase (SR 29142) to prevent hyperuricaemia during chemotherapy for haematological malignancies.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n", "\n\n
\n\n
\n\n \n\n
\n \n \n \n

\n Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.\n

\n \n \n\n \n \n \n \n \n \n
\n\n
\n\n
\n\n\n" ], "more": "\n\n \n \n Load More\n \n \n\n", "msg": "" }